Aclarion announces participation at the nass 37th annual meeting

Nociscan utilized within unprecedented nih heal initiative featured at nass 2022 nociscantm is the first evidence-supported saas platform to objectively analyze intradiscal pain nociscan bridges major diagnostic void between mri and provocative discography broomfield, co / accesswire / october 10, 2022 / aclarion, inc., ("aclarion" or the "company") (nasdaq:acon)(nasdaq:aconw), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain (clbp), announced today their participation at the north american spine society (nass) 37th annual meeting. aclarion executives, brent ness and ryan bond, will be attending the nass meeting with industry-leading physicians and attending the case presentation on the national institute of health's helping to end addiction long-term initiative (nih heal), wednesday, october 12th at 3pm ct.
ACON Ratings Summary
ACON Quant Ranking